

# Immune Thrombocytopenic Purpura Therapeutics- Asia Pacific Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/I3AE9A9E847MEN.html>

Date: March 2018

Pages: 160

Price: US\$ 3,480.00 (Single User License)

ID: I3AE9A9E847MEN

## Abstracts

### Report Summary

Immune Thrombocytopenic Purpura Therapeutics-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Immune Thrombocytopenic Purpura Therapeutics industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Asia Pacific and Regional Market Size of Immune Thrombocytopenic Purpura Therapeutics 2013-2017, and development forecast 2018-2023

Main market players of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific, with company and product introduction, position in the Immune Thrombocytopenic Purpura Therapeutics market

Market status and development trend of Immune Thrombocytopenic Purpura Therapeutics by types and applications

Cost and profit status of Immune Thrombocytopenic Purpura Therapeutics, and marketing status

Market growth drivers and challenges

The report segments the Asia Pacific Immune Thrombocytopenic Purpura Therapeutics market as:

Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue

and Growth Rate 2013-2023):

China  
Japan  
Korea  
India  
Southeast Asia  
Australia

Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Eltrombopag Olamine  
Fostamatinib Disodium  
GL-2045  
Avatrombopag  
BI-655064  
Others

Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital  
Clinic  
Others

Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market: Players Segment Analysis (Company and Product introduction, Immune Thrombocytopenic Purpura Therapeutics Sales Volume, Revenue, Price and Gross Margin):

Amgen Inc.  
Baxalta Incorporated  
Boehringer Ingelheim GmbH  
Bristol-Myers Squibb Company  
Eisai  
Hansa Medical AB  
Immunomedics, Inc.  
Intas Pharmaceuticals Ltd.  
Jiangsu Hengrui Medicine Co., Ltd.  
Merck & Co., Inc.  
Momenta Pharmaceuticals, Inc.

Novartis AG  
Pfizer Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF IMMUNE THROMBOCYTOPENIC PURPURA THERAPEUTICS**

- 1.1 Definition of Immune Thrombocytopenic Purpura Therapeutics in This Report
- 1.2 Commercial Types of Immune Thrombocytopenic Purpura Therapeutics
  - 1.2.1 Eltrombopag Olamine
  - 1.2.2 Fostamatinib Disodium
  - 1.2.3 GL-2045
  - 1.2.4 Avatrombopag
  - 1.2.5 BI-655064
  - 1.2.6 Others
- 1.3 Downstream Application of Immune Thrombocytopenic Purpura Therapeutics
  - 1.3.1 Hospital
  - 1.3.2 Clinic
  - 1.3.3 Others
- 1.4 Development History of Immune Thrombocytopenic Purpura Therapeutics
- 1.5 Market Status and Trend of Immune Thrombocytopenic Purpura Therapeutics 2013-2023
  - 1.5.1 Asia Pacific Immune Thrombocytopenic Purpura Therapeutics Market Status and Trend 2013-2023
  - 1.5.2 Regional Immune Thrombocytopenic Purpura Therapeutics Market Status and Trend 2013-2023

### **CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific 2013-2017
- 2.2 Consumption Market of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Regions
  - 2.2.1 Consumption Volume of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Regions
  - 2.2.2 Revenue of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Regions
- 2.3 Market Analysis of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Regions
  - 2.3.1 Market Analysis of Immune Thrombocytopenic Purpura Therapeutics in China 2013-2017

2.3.2 Market Analysis of Immune Thrombocytopenic Purpura Therapeutics in Japan 2013-2017

2.3.3 Market Analysis of Immune Thrombocytopenic Purpura Therapeutics in Korea 2013-2017

2.3.4 Market Analysis of Immune Thrombocytopenic Purpura Therapeutics in India 2013-2017

2.3.5 Market Analysis of Immune Thrombocytopenic Purpura Therapeutics in Southeast Asia 2013-2017

2.3.6 Market Analysis of Immune Thrombocytopenic Purpura Therapeutics in Australia 2013-2017

2.4 Market Development Forecast of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific 2018-2023

2.4.1 Market Development Forecast of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific 2018-2023

2.4.2 Market Development Forecast of Immune Thrombocytopenic Purpura Therapeutics by Regions 2018-2023

## **CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole Asia Pacific Market Status by Types

3.1.1 Consumption Volume of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Types

3.1.2 Revenue of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Types

3.2 Asia Pacific Market Status by Types in Major Countries

3.2.1 Market Status by Types in China

3.2.2 Market Status by Types in Japan

3.2.3 Market Status by Types in Korea

3.2.4 Market Status by Types in India

3.2.5 Market Status by Types in Southeast Asia

3.2.6 Market Status by Types in Australia

3.3 Market Forecast of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Types

## **CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Downstream Industry

- 4.2 Demand Volume of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry in China
  - 4.2.2 Demand Volume of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry in Japan
  - 4.2.3 Demand Volume of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry in Korea
  - 4.2.4 Demand Volume of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry in India
  - 4.2.5 Demand Volume of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry in Southeast Asia
  - 4.2.6 Demand Volume of Immune Thrombocytopenic Purpura Therapeutics by Downstream Industry in Australia
- 4.3 Market Forecast of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IMMUNE THROMBOCYTOPENIC PURPURA THERAPEUTICS**

- 5.1 Asia Pacific Economy Situation and Trend Overview
- 5.2 Immune Thrombocytopenic Purpura Therapeutics Downstream Industry Situation and Trend Overview

## **CHAPTER 6 IMMUNE THROMBOCYTOPENIC PURPURA THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC**

- 6.1 Sales Volume of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Major Players
- 6.2 Revenue of Immune Thrombocytopenic Purpura Therapeutics in Asia Pacific by Major Players
- 6.3 Basic Information of Immune Thrombocytopenic Purpura Therapeutics by Major Players
  - 6.3.1 Headquarters Location and Established Time of Immune Thrombocytopenic Purpura Therapeutics Major Players
  - 6.3.2 Employees and Revenue Level of Immune Thrombocytopenic Purpura Therapeutics Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News

- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

## **CHAPTER 7 IMMUNE THROMBOCYTOPENIC PURPURA THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

### 7.1 Amgen Inc.

#### 7.1.1 Company profile

#### 7.1.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

#### 7.1.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Amgen Inc.

### 7.2 Baxalta Incorporated

#### 7.2.1 Company profile

#### 7.2.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

#### 7.2.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Baxalta Incorporated

### 7.3 Boehringer Ingelheim GmbH

#### 7.3.1 Company profile

#### 7.3.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

#### 7.3.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH

### 7.4 Bristol-Myers Squibb Company

#### 7.4.1 Company profile

#### 7.4.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

#### 7.4.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

### 7.5 Eisai

#### 7.5.1 Company profile

#### 7.5.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

#### 7.5.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Eisai

### 7.6 Hansa Medical AB

#### 7.6.1 Company profile

#### 7.6.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

#### 7.6.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Hansa Medical AB

### 7.7 Immunomedics, Inc.

#### 7.7.1 Company profile

#### 7.7.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

7.7.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Immunomedics, Inc.

7.8 Intas Pharmaceuticals Ltd.

7.8.1 Company profile

7.8.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

7.8.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Intas Pharmaceuticals Ltd.

7.9 Jiangsu Hengrui Medicine Co., Ltd.

7.9.1 Company profile

7.9.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

7.9.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Jiangsu Hengrui Medicine Co., Ltd.

7.10 Merck & Co., Inc.

7.10.1 Company profile

7.10.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

7.10.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.

7.11 Momenta Pharmaceuticals, Inc.

7.11.1 Company profile

7.11.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

7.11.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Momenta Pharmaceuticals, Inc.

7.12 Novartis AG

7.12.1 Company profile

7.12.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

7.12.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Novartis AG

7.13 Pfizer Inc.

7.13.1 Company profile

7.13.2 Representative Immune Thrombocytopenic Purpura Therapeutics Product

7.13.3 Immune Thrombocytopenic Purpura Therapeutics Sales, Revenue, Price and Gross Margin of Pfizer Inc.

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMMUNE THROMBOCYTOPENIC PURPURA THERAPEUTICS**

8.1 Industry Chain of Immune Thrombocytopenic Purpura Therapeutics

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis



## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IMMUNE THROMBOCYTOPENIC PURPURA THERAPEUTICS**

- 9.1 Cost Structure Analysis of Immune Thrombocytopenic Purpura Therapeutics
- 9.2 Raw Materials Cost Analysis of Immune Thrombocytopenic Purpura Therapeutics
- 9.3 Labor Cost Analysis of Immune Thrombocytopenic Purpura Therapeutics
- 9.4 Manufacturing Expenses Analysis of Immune Thrombocytopenic Purpura Therapeutics

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF IMMUNE THROMBOCYTOPENIC PURPURA THERAPEUTICS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Immune Thrombocytopenic Purpura Therapeutics-Asia Pacific Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/I3AE9A9E847MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I3AE9A9E847MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

